Article
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Cancer discovery - 2 Nov 2022
Noronha Ashish, Belugali Nataraj Nishanth, Lee Joo Sang, Zhitomirsky Benny, Oren Yaara, Oster Sara, Lindzen Moshit, Mukherjee Saptaparna, Will Rainer, Ghosh Soma, Simoni-Nieves Arturo, Verma Aakanksha, Chatterjee Rishita, Borgoni Simone, Robinson Welles, Sinha Sanju, Brandis Alexander, Kerr D Lucas, Wu Wei, Sekar Arunachalam, Giri Suvendu, Chung Youngmin, Drago-Garcia Diana, Danysh Brian P, Lauriola Mattia, Fiorentino Michelangelo, Ardizzoni Andrea, Oren Moshe, Blakely Collin M, Ezike Jideofor, Wiemann Stefan, Parida Laxmi, Bivona Trever G, Aqeilan Rami I, Brugge Joan S, Regev Aviv, Getz Gad, Ruppin Eytan, Yarden Yosef
Abstract excerpt
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether the treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells and in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.